|Cubist Announces EMA Acceptance of Tedizolid Marketing Authorization ...|
Tedizolid is a once daily oxazolidinone being developed for both intravenous (I.V.) and oral administration for the treatment of serious infections caused by certain Gram-positive bacteria, including those caused by methicillin-resistant Staphylococcus ...
The Herald | HeraldOnline.com (press release) - Thu, 27 Feb 2014 04:33
|Durata Therapeutics Inc (DRTX) news: Analysts are bullish on Durata|
The company's lead product is delbavancin, an IV antibacterial for adult patients with acute skin and skin structure infections caused by Gram-positive bacteria. 79 mutual funds have positions, up from 68 a year earlier. Shares currently exchange hands ...
Seeking Alpha - Thu, 06 Mar 2014 06:53
|Intravenous antibiotic oritavancin approved for priority review by FDA|
The medication is used to treat acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus. “We look forward to working with the FDA during the review process ...
Vaccine News Daily - Fri, 21 Feb 2014 09:04
|The Medicines Company's oritavancin NDA accepted by FDA|
Pharmaceutical Business Review - Thu, 20 Feb 2014 22:42
|European Medicines Agency Accepts Marketing Authorization Application for ...|
Oritavancin is an investigational intravenous antibiotic for which The Medicines Company is seeking approval for the treatment of cSSTI (known as acute bacterial skin and skin structure infections (ABSSSIs) in the US) caused by susceptible gram ...
Wall Street Journal - Thu, 27 Feb 2014 05:41
|The Medicines Company's MAA for oritavancin for acute bacterial skin and skin ...|
MENAFN.COM - Fri, 28 Feb 2014 03:57
|Medicines Co.'s MAA On Oritavancin Accepted In EU - Quick Facts|
RTT News - Thu, 27 Feb 2014 05:41
|Soligenix Announces $300000 NIAID SBIR Grant Award Supporting Further ...|
SGX943 has been comprehensively evaluated in bacterial infection models and has shown preclinical efficacy with Gram-positive methicillin resistant Staphylococcus aureus (MRSA) as well as with other Gram-negative pathogens. As an innate defense ...
SYS-CON Media (press release) - Fri, 14 Feb 2014 04:11
|Soligenix Wins $300K Grant to Further Develop Melioidosis Treatment|
Genetic Engineering News - Fri, 14 Feb 2014 07:19
|FDA Accepts Filing of the Medicines Company's New Drug Application for ...|
The Medicines Company is seeking approval of oritavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), ...
DigitalJournal.com - Wed, 19 Feb 2014 03:26
|FDA to review The Medicines Co's new antibiotic|
PharmaTimes - Wed, 19 Feb 2014 14:18
|Today's Biggest Biotech Stories: Chelsea, Novartis, and The Medicines Company|
DailyFinance - Wed, 19 Feb 2014 07:11
|EMA accepts Cubist's tedizolid MAA for review|
Tedizolid is a once daily oxazolidinone being developed for both intravenous (IV) and oral administration for the treatment of serious infections caused by certain Gram-positive bacteria, including those caused by methicillin-resistant Staphylococcus ...
pharmabiz.com - Fri, 28 Feb 2014 21:37
|Durata Therapeutics to Announce Full Year 2013 Financial Results on March 14 ...|
Durata has completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, under investigation for the treatment of patients with acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria.
Wall Street Journal - Fri, 07 Mar 2014 04:56